CO6280491A2 - Granulacion en humedo que utiliza secuestrante de agua - Google Patents
Granulacion en humedo que utiliza secuestrante de aguaInfo
- Publication number
- CO6280491A2 CO6280491A2 CO10067826A CO10067826A CO6280491A2 CO 6280491 A2 CO6280491 A2 CO 6280491A2 CO 10067826 A CO10067826 A CO 10067826A CO 10067826 A CO10067826 A CO 10067826A CO 6280491 A2 CO6280491 A2 CO 6280491A2
- Authority
- CO
- Colombia
- Prior art keywords
- trimethoxyphenylamino
- oxazin
- pyrido
- ylamino
- pyrimidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describen tabletas que comprenden formulaciones estables hidrolíticamente de sal disódica de (6-(5-flúor-2-(3,4, 5-trimetoxifenilamino)pirimidin-4-ilamino) -2,2-dimetil-3-oxo-2H-pirido[3,2-b][1,4]oxazin-4(3H)-il)metil fosfato (compuesto 1) preparado por un proceso de granulación en húmedo.1.- Una formulación granulada en húmedo caracterizada porque comprende agua, una cantidad eficaz de sal disódica de (6-(5-flúor-2-(3,4,5-trimetoxifenilamino) pirimidin-4-ilamino)-2, 2-dimetil-3-oxo-2H-pirido[3,2-b][1,4]oxazin-4(3H)-il)metil fosfato y una cantidad suficiente de un agente secuestrante de agua para inhibir la descomposición de sal disódica de (6-(5-flúor-2-(3,4,5-trimetoxifenilamino)pirimidin-4-ilamino)-2,2-dimetil-3-oxo-2H-pirido[3,2-b][1,4]oxazin-4(3H)-il)metil fosfato, en donde la formulación, después de secado, tiene una densidad en masa suficiente para formar tabletas que tienen una dureza en el intervalo de aproximadamente 6kp hasta aproximadamente 30 kp.2.- La formulación de conformidad con la reivindicación 1, caracterizada porque después de secar la formulación tiene una densidad en masa de entre aproximadamente 0.35 hasta aproximadamente 0.65 g/mL.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98623707P | 2007-11-07 | 2007-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6280491A2 true CO6280491A2 (es) | 2011-05-20 |
Family
ID=40623940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10067826A CO6280491A2 (es) | 2007-11-07 | 2010-06-04 | Granulacion en humedo que utiliza secuestrante de agua |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US8263122B2 (es) |
| EP (1) | EP2217241B1 (es) |
| JP (1) | JP5567487B2 (es) |
| KR (2) | KR20150129067A (es) |
| CN (1) | CN101998857A (es) |
| AU (1) | AU2008323938B2 (es) |
| BR (1) | BRPI0820389A2 (es) |
| CA (1) | CA2704474C (es) |
| CO (1) | CO6280491A2 (es) |
| CR (1) | CR11476A (es) |
| CU (1) | CU23915B1 (es) |
| CY (1) | CY1122163T1 (es) |
| DK (1) | DK2217241T3 (es) |
| DO (1) | DOP2010000136A (es) |
| EA (1) | EA020210B1 (es) |
| EC (1) | ECSP10010233A (es) |
| ES (1) | ES2672519T3 (es) |
| HN (1) | HN2010000930A (es) |
| HR (1) | HRP20181174T1 (es) |
| HU (1) | HUE039193T2 (es) |
| IL (1) | IL205204A (es) |
| LT (1) | LT2217241T (es) |
| MX (1) | MX2010004733A (es) |
| MY (1) | MY169761A (es) |
| NI (1) | NI201000078A (es) |
| NZ (1) | NZ585913A (es) |
| PL (1) | PL2217241T3 (es) |
| PT (1) | PT2217241T (es) |
| RS (1) | RS57525B1 (es) |
| SG (1) | SG185961A1 (es) |
| SI (1) | SI2217241T1 (es) |
| TR (1) | TR201807879T4 (es) |
| UA (1) | UA102825C2 (es) |
| WO (1) | WO2009061909A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080223392A1 (en) * | 2007-03-14 | 2008-09-18 | L'oreal | Process for relaxing or straightening hair |
| GB0814688D0 (en) | 2008-08-12 | 2008-09-17 | Knauf Insulation | Thermal insulation product |
| ES2667026T3 (es) * | 2009-09-07 | 2018-05-09 | Argenta Manufacturing Limited | Preparaciones antihelmínticas granuladas y sistemas de administración |
| AU2011218805A1 (en) * | 2010-02-24 | 2012-08-30 | Auspex Pharmaceuticals, Inc. | Trimethoxyphenyl inhibitors of tyrosine kinase |
| UY34223A (es) * | 2011-07-28 | 2013-02-28 | Astrazeneca Ab | Formulaciones de (trimetoxifenilamino)pirimidinilo nuevas |
| US20180296579A1 (en) | 2015-04-24 | 2018-10-18 | Rigel Pharmaceuticals, Inc. | Methods of treating ibrutinib-resistant disease |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4904477A (en) * | 1987-07-08 | 1990-02-27 | American Home Products Corporation | Spray dried ibuprofen compositions |
| US5763172A (en) * | 1992-01-21 | 1998-06-09 | Board Of Regents, The University Of Texas System | Method of phosphate ester hydrolysis |
| US5358652A (en) * | 1992-10-26 | 1994-10-25 | Ethyl Petroleum Additives, Limited | Inhibiting hydrolytic degradation of hydrolyzable oleaginous fluids |
| WO1999033846A2 (en) * | 1997-12-31 | 1999-07-08 | The University Of Kansas | Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof |
| US6238677B1 (en) * | 1998-08-18 | 2001-05-29 | The United States Of America As Represented By The Secretary Of Agriculture | Starch microcapsules for delivery of active agents |
| US6716453B1 (en) * | 1999-05-20 | 2004-04-06 | Verion, Inc. | Method for increasing the active loading of compressible composition forms |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US20030215502A1 (en) * | 2002-03-20 | 2003-11-20 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
| US20060018972A1 (en) * | 2002-11-26 | 2006-01-26 | Upm Pharmaceuticals, Inc. | Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| ITMI20040498A1 (it) * | 2004-03-16 | 2004-06-16 | Solvay Solexis Spa | Composizioni granulari |
| ATE451381T1 (de) * | 2005-01-19 | 2009-12-15 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US8227455B2 (en) * | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| RU2012112552A (ru) * | 2009-08-31 | 2013-10-10 | Дипомед, Инк. | Удерживаемые в желудке фармацевтические композиции для немедленного и продленного высвобождения ацетаминофена |
| US20110237609A1 (en) * | 2010-03-29 | 2011-09-29 | Chelsea Therapeutics, Inc. | Antifolate compositions |
-
2008
- 2008-11-06 HU HUE08848427A patent/HUE039193T2/hu unknown
- 2008-11-06 EA EA201070570A patent/EA020210B1/ru not_active IP Right Cessation
- 2008-11-06 LT LTEP08848427.4T patent/LT2217241T/lt unknown
- 2008-11-06 CA CA2704474A patent/CA2704474C/en active Active
- 2008-11-06 KR KR1020157031730A patent/KR20150129067A/ko not_active Application Discontinuation
- 2008-11-06 AU AU2008323938A patent/AU2008323938B2/en active Active
- 2008-11-06 RS RS20180851A patent/RS57525B1/sr unknown
- 2008-11-06 EP EP08848427.4A patent/EP2217241B1/en active Active
- 2008-11-06 NZ NZ585913A patent/NZ585913A/en unknown
- 2008-11-06 MX MX2010004733A patent/MX2010004733A/es active IP Right Grant
- 2008-11-06 DK DK08848427.4T patent/DK2217241T3/en active
- 2008-11-06 US US12/266,337 patent/US8263122B2/en active Active
- 2008-11-06 MY MYPI2010001805A patent/MY169761A/en unknown
- 2008-11-06 JP JP2010532340A patent/JP5567487B2/ja active Active
- 2008-11-06 ES ES08848427.4T patent/ES2672519T3/es active Active
- 2008-11-06 KR KR1020107012273A patent/KR101663838B1/ko active IP Right Grant
- 2008-11-06 CN CN2008801195118A patent/CN101998857A/zh active Pending
- 2008-11-06 BR BRPI0820389-0A patent/BRPI0820389A2/pt not_active Application Discontinuation
- 2008-11-06 UA UAA201006878A patent/UA102825C2/ru unknown
- 2008-11-06 PL PL08848427T patent/PL2217241T3/pl unknown
- 2008-11-06 WO PCT/US2008/082618 patent/WO2009061909A2/en active Application Filing
- 2008-11-06 PT PT88484274T patent/PT2217241T/pt unknown
- 2008-11-06 SI SI200831981T patent/SI2217241T1/sl unknown
- 2008-11-06 SG SG2012081980A patent/SG185961A1/en unknown
- 2008-11-06 TR TR2018/07879T patent/TR201807879T4/tr unknown
-
2010
- 2010-04-19 IL IL205204A patent/IL205204A/en active IP Right Grant
- 2010-05-05 CU CU2010000089A patent/CU23915B1/es not_active IP Right Cessation
- 2010-05-06 DO DO2010000136A patent/DOP2010000136A/es unknown
- 2010-05-06 HN HN2010000930A patent/HN2010000930A/es unknown
- 2010-05-06 NI NI201000078A patent/NI201000078A/es unknown
- 2010-06-03 CR CR11476A patent/CR11476A/es not_active Application Discontinuation
- 2010-06-04 EC EC2010010233A patent/ECSP10010233A/es unknown
- 2010-06-04 CO CO10067826A patent/CO6280491A2/es not_active Application Discontinuation
-
2012
- 2012-07-26 US US13/559,097 patent/US8372415B2/en active Active
-
2013
- 2013-01-10 US US13/738,458 patent/US8652492B2/en active Active
-
2018
- 2018-07-20 HR HRP20181174TT patent/HRP20181174T1/hr unknown
- 2018-07-24 CY CY20181100772T patent/CY1122163T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6280491A2 (es) | Granulacion en humedo que utiliza secuestrante de agua | |
| AR110010A2 (es) | Composición farmacéutica formulada en una forma de dosis única de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo | |
| CR7899A (es) | Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa | |
| SV2004001418A (es) | Formulaciones farmaceuticas de 5,7,14-triazaciclo 10.3.1.0.2,11.04,9) -hexadeca-2(11),3,5,7,9-pentaeno" ref.pc 23248 | |
| NI201400100A (es) | Formulaciones farmacéuticas novedosas | |
| HRP20040323C1 (hr) | Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance | |
| BRPI0620063B8 (pt) | composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração | |
| PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
| MX2008011823A (es) | Forma de dosificacion solida que contiene un agente activo de sabor encubierto. | |
| BRPI0410044A (pt) | forma de dosagem contendo pantoprazol como ingrediente ativo | |
| AR067048A1 (es) | Formulaciones acuosas de acetaminofen para inyeccion. | |
| AR025879A1 (es) | Granulaciones de celulosa hidrolizada de sales de farmacos | |
| TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
| PE20061352A1 (es) | Composicion farmaceutica que comprende valopicitabina (val-mcyd) | |
| AR067047A1 (es) | Formulaciones acuosas de acetaminofen para inyeccion. | |
| EA201070626A1 (ru) | Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества | |
| AR040306A1 (es) | Capsula de liberacion controlada para la administracion de formulacion liquida | |
| HN2006023741A (es) | " formulaciones de liberacion prolongada de principios activos de zolpidem hemitartrato" | |
| AR074689A1 (es) | Formulaciones farmaceuticas de desintegracion rapida pre-compactadas de compuestos con baja biodisponibilidad oral. proceso de preparacion | |
| GR1004660B (el) | Βελτιωμενες φαρμακευτικες συνθεσεις του τριυδρικου αλενδρονικου νατριου και μεθοδοι παρασκευης τους | |
| ES2170645B1 (es) | Forma farmaceutica solida de administracion oral de una sal de metamizol soluble en agua, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. | |
| CO5330617A1 (es) | Nueva forma solida de dosificacion oral de 5-[2-etoxi-5 (4-metilpiperazin-1-il sulfonil) fenil]-1,6-dihidro-1-metil- 3-propilpirazolo[4,3-d]pirimidin-7-ona citrato y proceso para su fabricacion | |
| TH64687A (th) | สารผสมตามสูตรของอิแบนโดรเนทที่มีขนาดยาสูง | |
| EA200401357A1 (ru) | Болеутоляющая композиция для перорального применения с регулируемым высвобождением опиоида | |
| RS49979B (sr) | Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |